How do we separate proven findings from marketing hype?
ED research spans one of medicine's best drug-development stories (sildenafil's accidental discovery as an angina drug whose side effect became the indication) and one of the supplement industry's worst markets (the 'male enhancement' aisle — adulterated products, illegal drug-spiking, and borrowed science). The field teaches sharp discrimination: real trials exist for citrulline and ginseng; the FDA's adulteration warnings exist for the rest of the shelf. We interpret the literature in the context of the Princeton Consensus and EAU guidance.
A field with excellent drugs and a terrible aisle teaches maximal label literacy:
Pfizer's angina candidate UK-92480 shows a consistent trial-dropping report: erections. The most famous pivot in drug development begins.
The first oral ED treatment reaches pharmacies — a hidden condition walks into doctors' offices by the millions, and the conversation changes forever.
The Massachusetts Male Aging Study maps ED's risk factors — and they are cardiac risk factors; ED is reclassified from primarily psychological to substantially vascular.
Coronary-disease cohorts reveal ED preceding cardiac events by years — the Princeton Consensus formalizes ED as a cardiovascular risk marker requiring workup.
Two years of diet and exercise restore a third of obese men to normal erectile function — the disease-modifying tier earns its RCT.
Tadalafil's daily low-dose option reframes treatment; citrulline and ginseng RCTs give the shelf two honest products; the enhancement aisle keeps earning FDA warnings.
POPULATION · 24 men with mild ED (EHS 3), 1.5 g daily
FINDING · Citrulline improved erection hardness scores, with half the treated group reaching EHS 4 (fully hard) versus 8% on placebo.
LIMITATION · Very small sample; mild-ED population only; the dose studied (1.5 g) sits below the 3 g used in vascular-function studies — graded honestly as a mild-ED, proof-of-mechanism trial.
POPULATION · 110 obese men (BMI ≥30) with ED, 2 years
FINDING · Intensive diet and exercise restored normal erectile function in roughly a third of the intervention group versus ~3% of controls — with dose-response to weight and metabolic change.
LIMITATION · Behavioral intervention (unblinded by nature); the motivated-participant effect is real; maintenance beyond two years inferred from metabolic literature.
POPULATION · 55 men with ED (mean age ~50), 6 months, ~half with venous leak physiology
FINDING · Daily pelvic-floor training restored normal erectile function in ~40% of men and improved most of the remainder — the veno-occlusive lock strengthened by its own muscles.
LIMITATION · Small sample, single center, no long-term follow-up; technique adherence defines real-world results — but the effect size in a drug-free intervention earns its place.
POPULATION · Men with established coronary disease and population cohorts
FINDING · ED onset preceded coronary symptoms by 2–3 years in angiography cohorts and predicted subsequent events — consolidating the 3–5-year warning framework.
LIMITATION · Observational; ED's shared risk factors make confounding inherent — but the temporal ordering (ED first, events later) and artery-size biology support the causal reading the Princeton Consensus adopted.
POPULATION · Marketed 'herbal' male-enhancement products, laboratory analyses
FINDING · Hundreds of products found adulterated with undeclared PDE5-inhibitor analogs — unapproved drug dosing sold as botanicals, sometimes at dangerous levels.
LIMITATION · Surveillance data by nature; the finding is not a study weakness but the category's defining feature — the reason this page's Chapter 7 exists.